Wall Street Zen Upgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to "Hold"

Key Points

• Wall Street Zen upgraded Mirum Pharmaceuticals from “sell” to “hold,” while broader analyst coverage remains favorable, with an average “Moderate Buy” rating and a consensus price target of $137.33.
• Mirum’s second-quarter revenue rose 37.9% year over year to $176.24 million, beating estimates, but its $1.06 per-share loss was wider than expected. Analysts expect the company to remain unprofitable this year.
• Recent concerns include an unexpected FDA request for a Phase 3 study, which could increase costs and delay development, as well as insider stock sales totaling about $7.2 million over the past three months.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Saturday.

A number of other equities research analysts have also recently commented on MIRM. Robert W. Baird set a $123.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday. JPMorgan Chase & Co. upped their price target on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an "overweight" rating in a research report on Thursday, July 2nd. Wolfe Research started coverage on shares of Mirum Pharmaceuticals in a research note on Tuesday, May 19th. They issued an "outperform" rating and a $145.00 price objective for the company. Weiss Ratings upgraded shares of Mirum Pharmaceuticals from a "sell (d-)" rating to a "sell (d)" rating in a research report on Thursday. Finally, Morgan Stanley set a $137.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $137.33.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM opened at $100.65 on Friday. The company has a quick ratio of 1.99, a current ratio of 2.86 and a debt-to-equity ratio of 1.28. The business has a 50-day simple moving average of $110.33 and a two-hundred day simple moving average of $101.79. The stock has a market cap of $6.14 billion, a price-to-earnings ratio of -6.92 and a beta of 0.52. Mirum Pharmaceuticals has a 52 week low of $57.79 and a 52 week high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The company had revenue of $176.24 million for the quarter, compared to analysts' expectations of $166.33 million. During the same period in the previous year, the firm earned ($0.12) earnings per share. The firm's quarterly revenue was up 37.9% on a year-over-year basis. On average, analysts expect that Mirum Pharmaceuticals will post -2.01 EPS for the current year.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 2,721 shares of the company's stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $120.00, for a total value of $326,520.00. Following the completion of the transaction, the senior vice president directly owned 3,114 shares in the company, valued at $373,680. This represents a 46.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 5,000 shares of the stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $122.25, for a total transaction of $611,250.00. Following the sale, the chief financial officer directly owned 42,181 shares of the company's stock, valued at approximately $5,156,627.25. This trade represents a 10.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 67,155 shares of company stock valued at $7,185,662. Corporate insiders own 8.32% of the company's stock.

Institutional Trading of Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Contravisory Investment Management Inc. grew its position in Mirum Pharmaceuticals by 2.3% in the second quarter. Contravisory Investment Management Inc. now owns 4,604 shares of the company's stock worth $539,000 after acquiring an additional 103 shares in the last quarter. Faithward Advisors LLC raised its position in Mirum Pharmaceuticals by 0.5% during the first quarter. Faithward Advisors LLC now owns 27,467 shares of the company's stock valued at $2,537,000 after purchasing an additional 126 shares during the period. Janney Montgomery Scott LLC raised its position in Mirum Pharmaceuticals by 6.7% during the fourth quarter. Janney Montgomery Scott LLC now owns 3,200 shares of the company's stock valued at $253,000 after purchasing an additional 200 shares during the period. Comerica Bank lifted its stake in shares of Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company's stock valued at $40,000 after purchasing an additional 278 shares during the last quarter. Finally, Osaic Holdings Inc. lifted its stake in shares of Mirum Pharmaceuticals by 46.5% in the 2nd quarter. Osaic Holdings Inc. now owns 1,106 shares of the company's stock valued at $56,000 after purchasing an additional 351 shares during the last quarter.

Trending Headlines about Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Second-quarter revenue reached $176.24 million, beating the $166.33 million consensus estimate and rising 37.9% year over year. Growth was driven by Livmarli and Mirum’s other bile-acid therapies. Management also raised its 2026 sales outlook, providing a favorable signal about demand and the company’s commercial trajectory. Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts remain broadly constructive despite reducing their targets. TD Cowen lowered its target to $140 and retained a “buy” rating; Citizens JMP cut its target to $137 but maintained “market outperform”; and HC Wainwright reduced its target to $140 while keeping a “buy” rating. These targets imply substantial potential upside from recent trading levels.
• Neutral Sentiment: Mirum reported a quarterly loss of $1.06 per share, wider than the $0.74 consensus loss and the $0.12 loss recorded a year earlier. The loss reflects continued investment in the company’s rare-disease pipeline, but it remains a near-term valuation concern. Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
• Negative Sentiment: Citizens warned that an “unexpected” FDA request for a Phase 3 study clouds Mirum’s near-term outlook. The additional regulatory requirement could delay development or approval plans, increase spending, and weigh on investor sentiment.
• Negative Sentiment: Senior Vice President Jolanda Howe sold 1,840 shares worth approximately $193,734, reducing her direct holdings by 59.1%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which lessens its signaling value, but the sale still adds a modest negative headline.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source